Jounce Therapeutics Probability of Future Stock Price Finishing Over 1.88
JNCEDelisted Stock | USD 1.88 0.00 0.00% |
Jounce |
Jounce Therapeutics Target Price Odds to finish over 1.88
The tendency of Jounce Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
1.88 | 90 days | 1.88 | about 16.51 |
Based on a normal probability distribution, the odds of Jounce Therapeutics to move above the current price in 90 days from now is about 16.51 (This Jounce Therapeutics probability density function shows the probability of Jounce Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Jounce Therapeutics has a beta of -1.25. This indicates as returns on its benchmark rise, returns on holding Jounce Therapeutics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Jounce Therapeutics is expected to outperform its benchmark. Moreover Jounce Therapeutics has an alpha of 1.0205, implying that it can generate a 1.02 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Jounce Therapeutics Price Density |
Price |
Predictive Modules for Jounce Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Jounce Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Jounce Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Jounce Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Jounce Therapeutics is not an exception. The market had few large corrections towards the Jounce Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Jounce Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Jounce Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.02 | |
β | Beta against Dow Jones | -1.25 | |
σ | Overall volatility | 0.38 | |
Ir | Information ratio | 0.11 |
Jounce Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Jounce Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Jounce Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.Jounce Therapeutics is not yet fully synchronised with the market data | |
Jounce Therapeutics may become a speculative penny stock | |
Jounce Therapeutics has a very high chance of going through financial distress in the upcoming years | |
The company reported the previous year's revenue of 82 M. Net Loss for the year was (50.92 M) with profit before overhead, payroll, taxes, and interest of 27.2 M. | |
Jounce Therapeutics currently holds about 148.56 M in cash with (28.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Over 85.0% of the company shares are owned by institutional investors |
Jounce Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Jounce Stock often depends not only on the future outlook of the current and potential Jounce Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Jounce Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding | 51.7 K | |
Cash And Short Term Investments | 189.5 M |
Jounce Therapeutics Technical Analysis
Jounce Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Jounce Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Jounce Therapeutics. In general, you should focus on analyzing Jounce Stock price patterns and their correlations with different microeconomic environments and drivers.
Jounce Therapeutics Predictive Forecast Models
Jounce Therapeutics' time-series forecasting models is one of many Jounce Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Jounce Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Jounce Therapeutics
Checking the ongoing alerts about Jounce Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Jounce Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Jounce Therapeutics is not yet fully synchronised with the market data | |
Jounce Therapeutics may become a speculative penny stock | |
Jounce Therapeutics has a very high chance of going through financial distress in the upcoming years | |
The company reported the previous year's revenue of 82 M. Net Loss for the year was (50.92 M) with profit before overhead, payroll, taxes, and interest of 27.2 M. | |
Jounce Therapeutics currently holds about 148.56 M in cash with (28.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Over 85.0% of the company shares are owned by institutional investors |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Jounce Stock
If you are still planning to invest in Jounce Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Jounce Therapeutics' history and understand the potential risks before investing.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |